Literature DB >> 1931606

In vivo 31P nuclear magnetic resonance spectroscopy of experimental murine tumours and human tumour xenografts: effects of blood flow modification.

J C Bremner1, C J Counsell, G E Adams, I J Stratford, P J Wood, J F Dunn, G K Radda.   

Abstract

The effect of hydralazine on tumours appears to vary depending on tumour type. Blood flow and radiation sensitivity decrease more in murine tumours than human tumour xenografts. In this study a comparison between various tumour types has been made using in vivo 31P nuclear magnetic resonance spectroscopy (NMRS) to follow the metabolic responses occurring after clamping or intravenous administration of hydralazine (5 mg kg-1). Large increases in the Pi/total phosphate ratio were found with the murine sarcomas, KHT and RIF-1 implanted into C3H/He mice. However little or no effect was seen for the two human xenografted tumours, HX118 and HT29 implanted in MFI nu/nu/01a mice. An intermediate response was observed for KHT tumours grown in nu/nu mice. All tumours showed a large response to clamping. The anaesthetic Hypnorm/Hypnovel has a great influence on the response of the tumour metabolism to hydralazine appearing to both prolong and increase the changes induced. There is evidence to support the theory that the changes in 31P spectra are related to the oxygen status of the tumours.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1931606      PMCID: PMC1977471          DOI: 10.1038/bjc.1991.414

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  19 in total

1.  Phosphorylated metabolites in tumors, tissues, and cell lines.

Authors:  T R Brown; R A Graham; B S Szwergold; W J Thoma; R A Meyer
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

2.  Correlations between 31P-NMR spectroscopy and tissue O2 tension measurements in a murine fibrosarcoma.

Authors:  P Vaupel; P Okunieff; F Kallinowski; L J Neuringer
Journal:  Radiat Res       Date:  1989-12       Impact factor: 2.841

3.  The effect of hydralazine on the tumor cytotoxicity of the hypoxic cell cytotoxin RSU-1069: evidence for therapeutic gain.

Authors:  D J Chaplin; B Acker
Journal:  Int J Radiat Oncol Biol Phys       Date:  1987-04       Impact factor: 7.038

4.  The energy metabolism of RIF-1 tumours following hydralazine.

Authors:  Z M Bhujwalla; G M Tozer; S B Field; R J Maxwell; J R Griffiths
Journal:  Radiother Oncol       Date:  1990-11       Impact factor: 6.280

5.  A new mouse tumor model system (RIF-1) for comparison of end-point studies.

Authors:  P R Twentyman; J M Brown; J W Gray; A J Franko; M A Scoles; R F Kallman
Journal:  J Natl Cancer Inst       Date:  1980-03       Impact factor: 13.506

6.  Vascular occlusion and tumour cell death.

Authors:  J Denekamp; S A Hill; B Hobson
Journal:  Eur J Cancer Clin Oncol       Date:  1983-02

Review 7.  Chemical modification of tumour blood flow.

Authors:  R L Jirtle
Journal:  Int J Hyperthermia       Date:  1988 Jul-Aug       Impact factor: 3.914

8.  Assessment of tumor energy and oxygenation status by bioluminescence, nuclear magnetic resonance spectroscopy, and cryospectrophotometry.

Authors:  W Mueller-Klieser; C Schaefer; S Walenta; E K Rofstad; B M Fenton; R M Sutherland
Journal:  Cancer Res       Date:  1990-03-15       Impact factor: 12.701

9.  Correlations between 31P NMR spectroscopy and 15O perfusion measurements in the RIF-1 murine tumor in vivo.

Authors:  J L Evelhoch; S A Sapareto; G H Nussbaum; J J Ackerman
Journal:  Radiat Res       Date:  1986-04       Impact factor: 2.841

10.  Hydralazine-enhanced selective heating of transmissible venereal tumor implants in dogs.

Authors:  W D Voorhees; C F Babbs
Journal:  Eur J Cancer Clin Oncol       Date:  1982-10
View more
  6 in total

Review 1.  Assessing the bioreductive effectiveness of the nitroimidazole RSU1069 and its prodrug RB6145: with particular reference to in vivo methods of evaluation.

Authors:  J C Bremner
Journal:  Cancer Metastasis Rev       Date:  1993-06       Impact factor: 9.264

2.  Effect of hydralazine in spontaneous tumours assessed by oxygen electrodes and 31P-magnetic resonance spectroscopy.

Authors:  M Nordsmark; R J Maxwell; P J Wood; I J Stratford; G E Adams; J Overgaard; M R Horsman
Journal:  Br J Cancer Suppl       Date:  1996-07

3.  31P magnetic resonance spectroscopy as a predictor of efficacy in photodynamic therapy using differently charged zinc phthalocyanines.

Authors:  J C Bremner; S R Wood; J K Bradley; J Griffiths; G E Adams; S B Brown
Journal:  Br J Cancer       Date:  1999-10       Impact factor: 7.640

4.  Stable bioenergetic status despite substantial changes in blood flow and tissue oxygenation in a rat tumour.

Authors:  P Vaupel; D K Kelleher; T Engel
Journal:  Br J Cancer       Date:  1994-01       Impact factor: 7.640

5.  31P-nuclear magnetic resonance spectroscopy in vivo of six human melanoma xenograft lines: tumour bioenergetic status and blood supply.

Authors:  H Lyng; D R Olsen; T E Southon; E K Rofstad
Journal:  Br J Cancer       Date:  1993-12       Impact factor: 7.640

6.  Direct evidence that hydralazine can induce hypoxia in both transplanted and spontaneous murine tumours.

Authors:  M R Horsman; M Nordsmark; M Høyer; J Overgaard
Journal:  Br J Cancer       Date:  1995-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.